{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:06:23Z","timestamp":1792595183547,"version":"4.5.0"},"reference-count":18,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.2967\/jnumed.118.215434","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:55:22Z","timestamp":1669978522000},"page":"738-743","source":"Crossref","is-referenced-by-count":76,"title":["Unspecific\n                    <sup>18<\/sup>\n                    F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Robert","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Telli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"2023042807151175000_64.5.738.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.08.028"},{"key":"2023042807151175000_64.5.738.2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"2023042807151175000_64.5.738.3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer: part ii\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol."},{"key":"2023042807151175000_64.5.738.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229187"},{"key":"2023042807151175000_64.5.738.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2023042807151175000_64.5.738.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234898"},{"key":"2023042807151175000_64.5.738.7","doi-asserted-by":"crossref","unstructured":"Seifert R Schafigh D Bogemann M Weckesser M Rahbar K . Detection of local relapse of prostate cancer with 18F-PSMA-1007. Clin Nucl Med. 2019;44:e394\u2013e395.","DOI":"10.1097\/RLU.0000000000002543"},{"key":"2023042807151175000_64.5.738.8","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023042807151175000_64.5.738.9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023042807151175000_64.5.738.10","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1007\/s00259-022-05745-5","article-title":"Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET\/CT for prostate cancer-a single-centre experience of PET-guided biopsies","volume":"49","author":"Vollnberg","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023042807151175000_64.5.738.11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"2023042807151175000_64.5.738.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2023042807151175000_64.5.738.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"2023042807151175000_64.5.738.14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med."},{"key":"2023042807151175000_64.5.738.15","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnig H Maurer A Thali Y . Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48:4483\u20134494.","DOI":"10.1007\/s00259-021-05424-x"},{"key":"2023042807151175000_64.5.738.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234914"},{"key":"2023042807151175000_64.5.738.17","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2023042807151175000_64.5.738.18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by radioligands in non-prostate disease\u2014current status and future perspectives","volume":"45","author":"Backhaus","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.118.215434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:19:50Z","timestamp":1682677190000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.118.215434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,4,28]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.2967\/jnumed.118.215434"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.118.215434","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}